Targeted Lung Therapy.

Ateleva™ is developing a minimally invasive airway platform that enables selective reinflation and localized treatment of collapsed lung segments in critically ill and surgical patients. Patents pending.

Disclaimer: Ateleva™ is an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration. The device is not available for sale and is intended for research, development, and demonstration purposes only. Any forward-looking statements regarding potential clinical use or benefits are subject to regulatory review and approval.

Targeted Lung Therapy.

Ateleva™ is developing a minimally invasive airway platform that enables selective reinflation and localized treatment of collapsed lung segments in critically ill and surgical patients. Patents pending.

Disclaimer: Ateleva is an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration. The device is not available for sale and is intended for research, development, and demonstration purposes only. Any forward-looking statements regarding potential clinical use or benefits are subject to regulatory review and approval.

Segmental lung collapse is common, clinically significant, and lacks a targeted treatment

Segmental and lobar lung collapse is a frequent complication across critical care, perioperative medicine, and interventional pulmonology. It impairs oxygenation, increases CO₂ retention, and limits visualization and access during bronchoscopic and diagnostic procedures.

Over 2 million patients require mechanical ventilation annually, and a meaningful proportion develop collapse that prolongs ventilation, increases infection risk, and drives longer hospital stays. Collapse also disrupts interventional workflows, including lung cancer bronchoscopy and procedural access to distal airways.

Despite its prevalence across care settings, clinicians lack a dedicated tool to selectively reopen a single collapsed lung segment at the bedside or during procedures.

Current management strategies are non-selective and not designed for segment-level therapy.

Clinicians rely on ventilator recruitment, bronchoscopy, airway clearance, and supportive techniques such as proning and physiotherapy. These approaches either increase pressure across the entire lung or provide indirect clearance without restoring ventilation to the specific collapsed region.

During interventional procedures, bronchoscopy enables visualization and suction but cannot achieve controlled reinflation of an isolated segment. As a result, air preferentially flows to already open lung regions, while collapsed segments remain untreated and procedural access may remain compromised.

No existing pulmonary tool provides targeted, controlled reinflation of a single lung segment.

Ateleva™ is developing a minimally invasive airway platform designed for both interventional and critical care settings, enabling targeted reinflation and localized therapy at the segmental level. This allows clinicians to reopen collapsed tissue while preserving the surrounding healthy lung and maintaining procedural visualization and access.

  • Temporary segmental airway isolation
  • Controlled, localized reinflation
  • Seamless integration with existing bronchoscopy workflows
  • No new capital equipment or complex training required
HealthyLobar Collapse